2025-12-28 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co Inc (MRK) based on the provided data.

**1) Return Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Merck & Co Inc is a global pharmaceutical company focused on innovative medicines, vaccines, and animal health products.

*   **Return Rates:**
    *   MRK Cumulative Return: 27.02%
    *   VOO (S&P 500) Cumulative Return: 103.21%
    *   Divergence: -80.6 (Relative Divergence: 18.5)

*   **Analysis:** MRK has significantly underperformed the S&P 500 over the analyzed period. The large negative divergence (-80.6%) indicates a substantial difference in cumulative returns, with VOO performing much better. The relative divergence of 18.5 suggests that the current divergence is closer to the minimum divergence observed historically.

*   **Alpha/Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2015-2017  | 1.0%  | 68.5% | -28.0% | 0.0  | 134.1  |
| 2016-2018  | 36.0% | 69.8% | 21.0%  | -0.0 | 182.1  |
| 2017-2019  | 40.0% | 69.8% | 18.0%  | 0.3  | 216.8  |
| 2018-2020  | 16.0% | 79.6% | -8.0%  | 0.3  | 195.0  |
| 2019-2021  | 2.0%  | 79.6% | -44.0% | 0.7  | 191.4  |
| 2020-2022  | 15.0% | 79.6% | 16.0%  | 0.7  | 277.1  |
| 2021-2023  | 33.0% | 79.6% | 31.0%  | 0.3  | 272.3  |
| 2022-2024  | -4.0% | 79.6% | -25.0% | 0.2  | 248.5  |
| 2023-2025  | -22.0% | 71.5% | -90.0% | 1.8  | 266.7  |

    *   **CAGR:** The Compound Annual Growth Rate (CAGR) shows inconsistent performance over the different periods, with negative CAGRs in the most recent periods (2022-2024 and 2023-2025).
    *   **MDD:** The Maximum Drawdown (MDD) is very high, indicating substantial potential losses during these periods.
    *   **Alpha:** Alpha is a measure of performance on a risk-adjusted basis. Negative Alpha values indicate underperformance compared to the benchmark. The significant negative Alpha in 2015-2017, 2018-2020, 2019-2021, and especially 2023-2025 suggest considerable underperformance relative to its risk.
    *   **Beta:** Beta measures the volatility of a stock relative to the market. The Beta values are generally low, suggesting that MRK's price movements are less sensitive to market fluctuations (except 2023-2025 period).
    *   **Cap(B):**  Shows the market capitalization in Billions.

**2) Recent Stock Price Fluctuations**

*   Close Price: 106.78
*   Previous Close: 106.45
*   Change: 0.31
*   5-day SMA: 104.816
*   20-day SMA: 101.2865
*   60-day SMA: 93.3136

*   **Analysis:** The stock price is currently above its 5-day, 20-day, and 60-day Simple Moving Averages (SMA). This suggests an upward trend in the short term.  The recent price change (0.31) indicates a slight increase in the closing price.

**3) RSI, PPO, and Expected Return Analysis**

*   Market Risk Indicator (MRI): 1.0 (High Investment Recommended)
*   RSI: 71.04
*   PPO: 0.3084
*   Hybrid Signal: cash_0%_Buy 100% of cash (2 shares - Very Safe - MRI:1.00)
*   Recent (20 days) relative divergence change: 1.3 (+) (단기상승 - Short-term rise)
*   Expected Return (%): -47.6

*   **Analysis:**
    *   **MRI:** An MRI of 1.0 suggests the algorithm currently views the investment as having very low risk, recommending high investment.
    *   **RSI:** An RSI of 71.04 indicates that the stock is approaching overbought territory (typically above 70). This suggests that the recent upward momentum may be unsustainable, and a pullback is possible.
    *   **PPO:** The Positive Price Oscillator (PPO) measures the momentum of a stock.  A PPO of 0.3084 suggests a slight bullish momentum.
    *   **Hybrid Signal:** The hybrid signal recommends using all available cash to buy the stock, which suggests confidence in the stock's potential.
    *   **Relative Divergence Change:** The positive change in relative divergence indicates a recent short-term rise.
    *   **Expected Return:** A negative expected return of -47.6% is highly concerning. It suggests that the model predicts substantial underperformance over the next two years if an investment is made at this point.

**4) Recent News & Significant Events**

*   **Positive Headlines:**
    *   MRK Stock Surges on BMO Upgrade
    *   Merck's Stock is Suddenly Soaring
    *   "Is Merck Stock’s Run Legitimate?" suggests the recent surge is being questioned.
*   **Negative Headlines:**
    *   MRK Stock Holdings Lowered by Kempner Capital Management Inc.
    *   Weekend Wrap (suggests a review, possibly mixed)
*   **Other News:**
    *   Dividend Increase

*   **Analysis:** The news articles present a mixed picture. The stock surge and analyst upgrade are positive, while the reduction in holdings by Kempner Capital Management is a negative signal. The dividend increase is generally seen as positive, signaling financial stability. The question of legitimacy around the recent run should make you cautious.

**4-2) Analyst Opinions**

*   Consensus: Buy (~1.90)
*   Target Price (avg/high/low): 110.04 / 139.00 / 83.00

*   **Analysis:** The analyst consensus is "Buy," suggesting positive sentiment. The average target price of $110.04 indicates a potential upside from the current price of $106.78. However, the wide range between the high and low target prices ($139.00 and $83.00 respectively) suggests considerable uncertainty among analysts.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-11-05 | 2.32 | 17.28 B$   |
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2025-11-05 | 1.25 | 16.66 B$   |

*   **Analysis:**
    *   The most recent EPS (Earnings Per Share) of 2.32 is significantly higher than the EPS reported in 2024-11-06, indicating strong earnings growth in the most recent quarter.
    *   Revenue has generally been increasing over the past few quarters, peaking at $17.28B in the most recent quarter.

**6) Financial Information (Revenue/Profitability & Capital/Profitability)**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B   | 77.69%        |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $51.85B   | 11.16%  |
| 2025-06-30   | $48.99B   | 9.04%   |
| 2025-03-31   | $48.34B   | 10.51%  |
| 2024-12-31   | $46.31B   | 8.08%   |
| 2024-09-30   | $44.50B   | 7.09%   |

*   **Analysis:**
    *   **Revenue and Profitability:** Revenues are generally trending upwards.  The profit margins are exceptionally high and relatively stable, indicating strong pricing power and efficient cost management.
    *   **Capital and Profitability:**  Equity has been consistently increasing, reflecting retained earnings and growth in the company's net worth. The Return on Equity (ROE) has also been improving, indicating better profitability relative to shareholders' equity.

**7) Comprehensive Analysis (Summary)**

*   **Underperformance vs. S&P 500:** MRK has significantly underperformed the S&P 500.
*   **Mixed Signals:**  While recent earnings, revenue, and profitability metrics are strong, the RSI suggests it might be overbought.
*   **Conflicting Indicators:** The MRI is very high investment recommended, whereas the expected return is very low.
*   **Analyst Sentiment:** Analysts have a consensus "Buy" rating, but there's a wide range in target prices, indicating uncertainty.
*   **Key Concern: Negative Expected Return:** The most critical concern is the negative expected return of -47.6%. This suggests the model anticipates significant underperformance from the current price level, *despite* the positive recent momentum and strong financials. The large MDD and alpha are of similar concerns.

**Overall Recommendation:**

The data presents a mixed picture. The positive earnings, revenue growth, strong profit margins, analyst buy ratings, and the hybrid signal indicating a buying opportunity are encouraging. However, the underperformance relative to the S&P 500, the high RSI (overbought potential), and, most importantly, the *significantly negative expected return* are serious red flags.

**Caution is advised.** Further investigation is needed to understand the drivers behind the negative expected return. Consider carefully the discrepancy between the strong recent performance and the concerning long-term outlook before making any investment decisions. It is possible that the model is predicting a major correction or a fundamental shift in the company's prospects. The high MDD values, especially, should concern any investors.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.